Meda Acquires Antula

Consistent step in Meda's OTC strategy
- Sales of about SEK 500 million with strong growth in the Nordic markets
- Well-established brands that will be launched internationally
- A strong pipeline of 3-4 new products that can be launched annually

Purchase price and time table
- Purchase consideration of SEK 1,800 million (on a debt-free basis)
- Financed using existing credit facilities
- The acquisition is expected to be completed within a couple of months

Meda has signed an agreement to acquire Antula with well-known brands such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox, and Inside. Antula is a growing company that concentrates on prescription-free (OTC) products. In five years, Antula has built strong brandnames and generated sales of some SEK 500 million just in the Nordics. Its integration with Meda opens doors to an international marketplace and broadens its potential through Meda's OTC organisation.

Meda has expressed its ambition to build a strong position in OTC products, an area that it has continually expanded in recent years. Antula’s and Meda's OTC products will together make up over 20% of Meda's total sales.

The acquisition of Antula offers Meda clear growth opportunities, partly through Meda and Antula's existing products, and partly through Antula's pipeline that consists of three to four new products annually. Antula is established in the Nordics with its own organization. Through the integration with Meda, several of the products will have potential to become internationally strong brands.

“We are pleased to welcome the Antula team to Meda. They have demonstrated their considerable expertise in consumer marketing and we are looking forward to an exciting future together," said Anders Lönner, CEO of Meda AB.

”I’m delighted that we have found a perfect home for Antula within Meda. This is the right step so we can unlock the value of Antula’s products on an international base with Meda’s organization. Antula’s pipeline also offers Meda an additional growth opportunity”, said Barry Clare, founder of Healthcare Brands International, Antula’s current owner.

The acquisition price for Antula is SEK 1,800 million on a debt-free basis. The acquisition will be financed using Meda's existing credit facilities. The transaction is subject to standard closing requirements and the approval of the competition authorities. The acquisition of Antula is expected to be completed within a couple of months.

Healthcare Brands International Limited

Healthcare Brands International Limited
OTC brand management

Website
www.meda.se

Downloads

DownloadFull Press Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera